Hedge fund manager Kyle Bass and his Coalition for Affordable Drugs are continuing their campaign against certain pharmaceutical patents, most recently seeking to invalidate patents owned by Celgene and NPS Pharma.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Kyle Bass, Coalition for Affordable Drugs, Celgene, NPS Pharma, inter partes review